704-03-0

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoro-2-Methoxybenzoyl chloride is used as a key intermediate for the synthesis of various pharmaceuticals. Its ability to undergo acylation reactions with a range of nucleophiles allows for the creation of diverse drug molecules, contributing to the development of new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Fluoro-2-Methoxybenzoyl chloride serves as a crucial building block in the production of pesticides and other agrochemicals. Its reactivity enables the synthesis of compounds with specific biological activities, enhancing crop protection and yield.
Used in Fine Chemicals Synthesis:
5-Fluoro-2-Methoxybenzoyl chloride is utilized as a versatile reagent in the preparation of fine chemicals, which are high-purity chemicals used in various applications such as fragrances, dyes, and specialty chemicals. Its unique properties facilitate the synthesis of complex organic molecules with specific functionalities.
Used in Research and Development:
5-Fluoro-2-Methoxybenzoyl chloride is also commonly used in research and development laboratories, where it aids in the exploration of new chemical reactions and the synthesis of novel organic compounds. Its role as an intermediate in the production of complex organic molecules is vital for advancing scientific knowledge and innovation in the field of organic chemistry.

Upstream product

• 394-04-7 5-fluoro-2-methoxybenzoic acid 

Downstream Products

• 1427-22-1 5-fluoro-2-methoxy-N-(3-morpholin-4-yl-propyl)-benzamide 
• 5710-39-4 5-Fluor-2-methoxy-benzoesaeure-<2-dimethylamino-aethylester> 
• 5710-40-7 5-Fluor-2-methoxy-benzoesaeure-<2-diisopropylamino-aethylester> 
• 5710-42-9 5-Fluor-2-methoxy-benzoesaeure-<3-dimethylamino-propylester> 
• 5710-43-0 5-Fluor-2-methoxy-benzoesaeure-<3-diaethylamino-propylester> 
• 5710-41-8 5-Fluor-2-methoxy-benzoesaeure-<2-dibutylamino-aethylester> 
• 5749-35-9 5-Fluor-2-methoxy-benzoesaeure-<3-dibutylamino-propylester> 
• 840490-27-9 6-[4-(5-fluoro-2-methoxybenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide 
• 1146161-90-1 2-(4-chloroquinazolin-2-yl)-4-fluorophenol 
• 1146160-83-9 C₁₅H₁₀ClFN₂O 
• 1311204-99-5 C₁₅H₁₁FN₂O₂ 
• 1262849-62-6 (R)-2-(4-(3-(dimethylamino)pyrrolidin-1-yl)quinazolin-2-yl)-4-fluorophenol 
• 1146161-64-9 4-fluoro-2-(4-((3S,5R)-5-(hydroxymethyl)pyrrolidin-3-ylamino)quinazolin-2-yl)phenol 

Relevant academic research and scientific papers

CYCLOALKYLIDENE CARBOXYLIC ACIDS AND DERIVATIVES AS BTK INHIBITORS

The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical compositions containing one or more such compounds, and to the use of such compounds and pharmaceutical compositions for the treatment of disorders involving mediation of BTK in humans (Formula I).

One-Pot Domino Friedel-Crafts Acylation/Annulation between Alkynes and 2-Methoxybenzoyl Chlorides: Synthesis of 2,3-Disubstituted Chromen-4-one Derivatives

A highly regioselective synthesis of 2,3-disubstituted chromen-4-one derivatives is accomplished from readily available internal alkynes and 2-methoxybenzoyl chlorides. The reaction proceeds via a domino intermolecular Friedel-Crafts acylation/intramolecular vinyl carbocation trapping (or oxa-Michael addition)/demethylation reaction sequence. This Lewis acid promoted method features relatively mild reaction conditions to synthesize a variety of 2,3-disubstituted chromen-4-one derivatives in one pot with up to 93% yield. The chromen-2-one (coumarin) product was obtained when 2,6-dimethoxybenzoyl chloride was used as a starting material via an electrophilic aromatic substitution/rearrangement process.

PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of t

COMPOUNDS USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

Marinopyrrole derivatives as potential antibiotic agents against methicillin-resistant Staphylococcus aureus (III)

The marine natural product, marinopyrrole A (1), was previously shown to have significant antibiotic activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Although compound (1) exhibits a significant reduction in MRSA activity in the presence of human serum, we have identified key modifications that partially restore activity. We previously reported our discovery of a chloro-derivative of marinopyrrole A (1a) featuring a 2-4 fold improved minimum inhibitory concentration (MIC) against MRSA, significantly less susceptibility to serum inhibition and rapid and concentration-dependent killing of MRSA. Here, we report a novel fluoro-derivative of marinopyrrole A (1e) showing an improved profile of potency, less susceptibility to serum inhibition, as well as rapid and concentration-dependent killing of MRSA.

Novel quinolizidine salicylamide influenza fusion inhibitors

A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC50 of 0.25 μg/mL in plaque reduction assay. The synthesis and the SAR of these compounds are discussed.

Synthesis and 5-HT-3 receptor binding activity of 5-[125I]iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl]benzamide and its 5-halogen-2-alkoxyl homologues

(S)-5-Iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide (MIZAC) was prepared from 5-iodo-2,3-dimethoxybenzoyl chloride and (S)-3-aminoquinuclidine. [125I]Iodode-stannylation of its corresponding 5-tri-n-butyltin derivative gave [125I]-MIZAC at 1800 Ci/mmol. Binding of [125I]-MIZAC in rat entorhinal cortex revealed a K(D) of 1.37 ± 0.21 nM. A series of racemic 2-O-alkyl derivatives of MIZAC were prepared and 5-HT-3 receptor affinities were determined by inhibition of [125I]-MIZAC binding. Optimal affinity for the receptor was obtained with small, electron-withdrawing substituents in the aromatic 5-position and with bulky substituents in the 3-position. [125I]-MIZAC is a selective radioligand useful for in vitro identification of the 5-HT-3 receptor.